Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates

分组1 - Atara Biotherapeutics reported a quarterly loss of $0.23 per share, better than the Zacks Consensus Estimate of a loss of $0.37, and an improvement from a loss of $0.72 per share a year ago, indicating a 37.84% earnings surprise [1] - The company generated revenues of $27.36 million for the quarter ended March 2024, surpassing the Zacks Consensus Estimate by 1.32%, and showing significant growth from $1.23 million in the same quarter last year [1] - Over the last four quarters, Atara Biotherapeutics has exceeded consensus EPS estimates two times and revenue estimates two times [1] 分组2 - The stock has gained approximately 10.3% since the beginning of the year, outperforming the S&P 500's gain of 8.8% [2] - The current consensus EPS estimate for the upcoming quarter is -$0.33 on revenues of $40 million, and for the current fiscal year, it is -$1.30 on revenues of $117 million [4] - The Medical - Biomedical and Genetics industry, to which Atara Biotherapeutics belongs, is currently ranked in the top 35% of over 250 Zacks industries, indicating a favorable outlook for the sector [5]